Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radiotherapy: Analysis of efficacy and long-term toxicity

Haematologica

Volumn 85, Issue 10, 2000, Pages 1032-1039

  Brusamolino, E ^a   Lunghi, F ^a   Orlandi, E ^a   Astori, C ^a   Passamonti, F ^a   Barate, C ^a   Pagnucco, G ^a   Baio, A ^a   Franchini, P ^a   Lazzarino, M ^a   Bernasconi, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

ABVD; Combined modality therapy; Early stage; Hodgkin's disease; Long term toxicity

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; BREAST CARCINOMA; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEMALE FERTILITY; HEART DILATATION; HEART DISEASE; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LUNG DISEASE; LUNG FIBROSIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; THYROID DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0033768356     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pathologic stages IA and IIA Hodgkin's disease: Results of treatment with radiotherapy alone (1968-1980)
2. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients with mantle and paraaortic irradiation
3. Radiation therapy in the management of Hodgkin's disease
4. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience
5. Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease
6. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease
7. Early-stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP
8. Stage I and II Hodgkin's disease: Involved field radiotherapy vs. extended-field radiotherapy vs. involved field radiotherapy followed by six cycles of MOPP
9. Early-stage Hodgkin's disease: Long-term results with radiotherapy alone or combined radiotherapy and chemotherapy
10. Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early-stage Hodgkin's disease
11. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease
12. Longterm results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy
13. Second acute leukemia and other malignancies following treatment for Hodgkin's disease
14. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: A case-control study
15. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: The Gruppo Italiano per lo Studio dei Linfomi experience
16. Stanford-Kaiser Permanente G1 study for clinical stage I and IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation
17. Treatment of early-stage Hodgkin's disease: Improved outcome with brief chemotherapy and radiotherapy without staging laparotomy
18. Treatment of early-stage Hodgkin's disease with ABVD and limited radiotherapy: Analysis of efficacy and long-term toxicity
19. Report of a committee convened to discuss the evaluation staging of patients with Hodgkin's disease. Cotswold Meeting
20. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imadazole carboxamide versus MOPP
21. Toxicity and response of the Eastern Cooperative Oncology Group
22. Nonparametric estimation from incomplete observations
23. Effects of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
24. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study
25. Hodgkin's disease. Complications of therapy and excess mortality
26. Long-term survival in Hodgkin's disease: Relative impact of mortality, second tumors, infections and cardiovascular disease
27. Thyroid diseases after treatment of Hodgkin's disease
28. Second malignant neoplasms complicating Hodgkin's disease
29. Risk of second cancers after treatment for Hodgkin's disease
30. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
31. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease
32. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome
33. Late complications of Hodgkin's disease management
34. Lung cancer following Hodgkin's disease. A case control study
35. Breast cancer and other second neoplasms after childhood Hodgkin's disease
36. Breast cancer after treatment of Hodgkin's disease
37. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease
38. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease
39. Fertility evaluation in patients with Hodgkin's disease
40. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results for MOPP and ABVD